CD81 通过阻断 CD274/PD-L1 的选择性自噬降解驱动放射抵抗性胶质母细胞瘤的免疫逃逸
CD81 drives immune evasion in radioresistant glioblastoma by blocking selective autophagic degradation of CD274/PD-L1.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
原发性脑肿瘤中免疫治疗相关中枢神经系统并发症
英文原题：Immunotherapy associated central nervous system complications in primary brain tumors.
查看英文原题
Immunotherapy associated central nervous system complications in primary brain tumors.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
对中枢神经系统（CNS）和脑肿瘤微环境中免疫系统遗传学及功能的认识不断加深，推动原发性脑肿瘤免疫治疗临床试验的势头和数量持续增加。颅外恶性肿瘤免疫治疗的神经系统并发症已有充分描述；但原发性脑肿瘤具有独特生理特征和治疗挑战，其免疫治疗相关CNS毒性正逐渐显现。本综述重点介绍原发性脑肿瘤免疫治疗相关的新兴且独特的CNS并发症，包括免疫检查点抑制剂、溶瘤病毒、过继细胞转移/嵌合抗原受体（CAR）T细胞和疫苗所致并发症，并回顾目前已应用或正在研究用于处理此类毒性的治疗方式。
展开英文摘要原文
Advances clarifying the genetics and function of the immune system within the central nervous system (CNS) and brain tumor microenvironment have led to increasing momentum and number of clinical trials using immunotherapy for primary brain tumors. While neurological complications of immunotherapy in extra-cranial malignancies is well described, the CNS toxicities of immunotherapy in patients with primary brain tumors with their own unique physiology and challenges are burgeoning.
This review highlights the emerging and unique CNS complications associated with immunotherapy including checkpoint inhibitors, oncolytic viruses, adoptive cell transfer/chimeric antigen receptor (CAR) T cell and vaccines for primary brain tumors, as well as reviews modalities that have been currently employed or are undergoing investigation for treatment of such toxicities.
论文信息
- 作者
- Mantica M、Drappatz J
- 单位
- Department of Neurology, University of Pittsburgh, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA, United States.United States
- 文献类型
- 综述
- 期刊
- Frontiers in oncology2023
- 原文标识
- PubMed 36874119 · DOI 10.3389/fonc.2023.1124198
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →